The mTOR Signaling Pathway is an Emerging Therapeutic Target in Multiple Myeloma

被引：28

作者：

Li, Jie ^{[1
]}

Zhu, Jingyu ^{[1
]}

Cao, Biyin ^{[1
]}

Mao, Xinliang ^{[1
]}

机构：

[1] Soochow Univ, Cyrus Tang Hematol Ctr, Suzhou 215123, Peoples R China

来源：

CURRENT PHARMACEUTICAL DESIGN | 2014年 / 20卷 / 01期

关键词：

Mammalian target of rapamycin ( mTOR); mTOR complex 1; mTOR complex 2; multiple myeloma; drug discovery; PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET; MAMMALIAN TARGET; RAPAMYCIN INHIBITOR; INCREASES CHEMOSENSITIVITY; CELL-PROLIFERATION; S6; KINASE; CANCER; COMPLEX; DEPTOR; PHOSPHORYLATION;

D O I：

10.2174/13816128113199990638

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The mammalian target of rapamycin ( mTOR) is a PI3K-related serine/threonine kinase and plays a critical role in modulating proliferation, growth, survival, invasion and chemoresistance of multiple myeloma, a malignancy of plasma cells. Since it was identified as the therapeutic target of rapamycin, mTOR has been applied for anti-cancer drug discovery. More and more mTOR inhibitors have been developed and demonstrated with great clinical potentials for multiple myeloma and other cancers. In this review, we highlighted advances in drug discovery targeting the mTOR signaling pathway for the treatment of multiple myeloma with an input from our recent studies.

引用

页码：125 / 135

页数：11

共 93 条

[1]

Abraham RT., 2009, FIPE RIMISP, V1, P8

[2]

Altomare DA, 2012, CURR MED CHEM, V19, P3748

[3] Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma [J].

Baumann, Philipp ;

Schneider, Laura ;

Mandl-Weber, Sonja ;

Oduncu, Fuat ;

Schmidmaier, Ralf .

ANTI-CANCER DRUGS, 2012, 23 (01) :131-138

[4] The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma [J].

Baumann, Philipp ;

Mandl-Weber, Sonia ;

Oduncu, Fuat ;

Schmidmaier, Ralf .

EXPERIMENTAL CELL RESEARCH, 2009, 315 (03) :485-497

[5] Rapamycin passes the torch: a new generation of mTOR inhibitors [J].

Benjamin, Don ;

Colombi, Marco ;

Moroni, Christoph ;

Hall, Michael N. .

NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (11) :868-880

[6] Mammalian target of rapamycin: Biological function and target for novel anticancer agents [J].

Borders, Emily B. ;

Bivona, Cory ;

Medina, Patrick J. .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (24) :2095-2106

[7] High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma [J].

Boyd, Kevin D. ;

Walker, Brian A. ;

Wardell, Christopher P. ;

Ross, Fiona M. ;

Gregory, Walter M. ;

Davies, Faith E. ;

Morgan, Gareth J. .

LEUKEMIA & LYMPHOMA, 2010, 51 (11) :2126-2129

[8] A MAMMALIAN PROTEIN TARGETED BY G1-ARRESTING RAPAMYCIN-RECEPTOR COMPLEX [J].

BROWN, EJ ;

ALBERS, MW ;

SHIN, TB ;

ICHIKAWA, K ;

KEITH, CT ;

LANE, WS ;

SCHREIBER, SL .

NATURE, 1994, 369 (6483) :756-758

[9] YEAST TOR (DRR) PROTEINS - AMINO-ACID-SEQUENCE ALIGNMENT AND IDENTIFICATION OF STRUCTURAL MOTIFS [J].

CAFFERKEY, R ;

MCLAUGHLIN, MM ;

YOUNG, PR ;

JOHNSON, RK ;

LIVI, GP .

GENE, 1994, 141 (01) :133-136

[10] Dissecting Bortezomib: Development, Application, Adverse Effects and Future Direction [J].

Cao, Biyin ;

Li, Jie ;

Mao, Xinliang .

CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (18) :3190-3200

← 1 2 3 4 5 6 7 8 9 10 →